Post Author: Alexey Aleshin, MD, MBA
Alexey Aleshin is general manager of early cancer detection and interim head of medical affairs of oncology, Natera. He can be reached on Twitter @aaleshin.
Dr. Aleshin was actively involved as an advisor and consultant at various companies focused on advancing the clinical adoption of next-generation sequencing technologies.
He received his MD and MBA from UCLA and later completed his residency at Stanford University Medical Center and his hematology-oncology fellowship at Stanford Hospital, where his research has focused on comprehensive genomic profiling, single-cell sequencing, and novel molecular residual disease technologies.
Alexey Aleshin is general manager of early cancer detection and interim head of medical affairs of oncology, Natera. He can be reached on Twitter @aaleshin.
Dr. Aleshin was actively involved as an advisor and consultant at various companies focused on advancing the clinical adoption of next-generation sequencing technologies.
He received his MD and MBA from UCLA and later completed his residency at Stanford University Medical Center and his hematology-oncology fellowship at Stanford Hospital, where his research has focused on comprehensive genomic profiling, single-cell sequencing, and novel molecular residual disease technologies.
Life can feel full of uncertainty when battling cancer, with few guarantees. “Is there still cancer in my body?” and “Will it come back?” are common questions that have long been difficult to answer confidently until recently. Advances in next-generation sequencing — and a growing understanding of how our bodies respond to illness and treatment — have brought us closer than ever to predicting our individual futures, at least when …
Read more…
